Perforin Rapidly Induces Plasma Membrane Phospholipid Flip-Flop

被引:40
作者
Metkar, Sunil S. [1 ]
Wang, Baikun [1 ]
Catalan, Elena [4 ]
Anderluh, Gregor [2 ]
Gilbert, Robert J. C. [3 ]
Pardo, Julian [4 ,5 ]
Froelich, Christopher J. [1 ]
机构
[1] NorthShore Univ, Dept Med, HealthSyst Res Inst, Evanston, IL 60201 USA
[2] Univ Ljubljana, Dept Biol, Biotech Fac, Ljubljana, Slovenia
[3] Henry Wellcome Bldg Genom Med, Div Struct Biol, Oxford, England
[4] Univ Zaragoza, Dept Bioquim & Biol Mol & Celullar, Zaragoza, Spain
[5] Fdn Aragon I D, Zaragoza, Spain
基金
美国国家卫生研究院;
关键词
PORE-FORMING PROTEIN; GRANZYME-B; TARGET-CELLS; CYTOSOLIC DELIVERY; EQUINATOXIN-II; GRANULES; CYTOTOXICITY; MECHANISM; DEATH; LYMPHOCYTES;
D O I
10.1371/journal.pone.0024286
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The cytotoxic cell granule secretory pathway is essential for host defense. This pathway is fundamentally a form of intracellular protein delivery where granule proteases (granzymes) from cytotoxic lymphocytes are thought to diffuse through barrel stave pores generated in the plasma membrane of the target cell by the pore forming protein perforin (PFN) and mediate apoptotic as well as additional biological effects. While recent electron microscopy and structural analyses indicate that recombinant PFN oligomerizes to form pores containing 20 monomers (20 nm) when applied to liposomal membranes, these pores are not observed by propidium iodide uptake in target cells. Instead, concentrations of human PFN that encourage granzyme-mediated apoptosis are associated with pore structures that unexpectedly favor phosphatidylserine flip-flop measured by Annexin-V and Lactadherin. Efforts that reduce PFN mediated Ca influx in targets did not reduce Annexin-V reactivity. Antigen specific mouse CD8 cells initiate a similar rapid flip-flop in target cells. A lipid that augments plasma membrane curvature as well as cholesterol depletion in target cells enhance flip-flop. Annexin-V staining highly correlated with apoptosis after Granzyme B (GzmB) treatment. We propose the structures that PFN oligomers form in the membrane bilayer may include arcs previously observed by electron microscopy and that these unusual structures represent an incomplete mixture of plasma membrane lipid and PFN oligomers that may act as a flexible gateway for GzmB to translocate across the bilayer to the cytosolic leaflet of target cells.
引用
收藏
页数:13
相关论文
共 57 条
[1]   Melittin-induced bilayer leakage depends on lipid material properties: Evidence for toroidal pores [J].
Allende, D ;
Simon, SA ;
McIntosh, TJ .
BIOPHYSICAL JOURNAL, 2005, 88 (03) :1828-1837
[2]   Fusion needs more than SNAREs [J].
Almers, W .
NATURE, 2001, 409 (6820) :567-568
[3]   Pore formation by equinatoxin II, a eukaryotic protein toxin, occurs by induction of nonlamellar lipid structures [J].
Anderluh, G ;
Dalla Serra, M ;
Viero, G ;
Guella, G ;
Macek, P ;
Menestrina, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (46) :45216-45223
[4]   The membrane-induced structure of melittin is correlated with the fluidity of the lipids [J].
Andersson, August ;
Biverstahl, Henrik ;
Nordin, Jon ;
Danielsson, Jens ;
Lindahl, Emma ;
Maler, Lena .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2007, 1768 (01) :115-121
[5]   All-or-None versus Graded Single-Vesicle Analysis Reveals Lipid Composition Effects on Membrane Permeabilization [J].
Apellaniz, Beatriz ;
Nieva, Jose L. ;
Schwille, Petra ;
Garcia-Saez, Ana J. .
BIOPHYSICAL JOURNAL, 2010, 99 (11) :3619-3628
[6]   Bax-type apoptotic proteins porate pure lipid bilayers through a mechanism sensitive to intrinsic monolayer curvature [J].
Basañez, G ;
Sharpe, JC ;
Galanis, J ;
Brandt, TB ;
Hardwick, JM ;
Zimmerberg, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (51) :49360-49365
[7]  
Browne KA, 1999, MOL CELL BIOL, V19, P8604
[8]  
CRIADO M, 1985, J IMMUNOL, V135, P4245
[9]   Vertical collapse of a cytolysin prepore moves its transmembrane β-hairpins to the membrane [J].
Czajkowsky, DM ;
Hotze, EM ;
Shao, ZF ;
Tweten, RK .
EMBO JOURNAL, 2004, 23 (16) :3206-3215
[10]  
DOURMASHKIN RR, 1980, CLIN EXP IMMUNOL, V42, P554